Luis Matamala
8 Papers
Luis Matamala is an academic researcher. The author has contributed to research in topics: Medicine & Nivolumab. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Hussein Abdul-Hassan Tawbi,Dirk Schadendorf,Evan J. Lipson,Paolo A. Ascierto,Luis Matamala,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,J.J. De Menezes,Stéphane Dalle,Ana Arance,Jean-Jacques Grob,Shivani Srivastava,Mena Abaskharoun,Melissa Hamilton,Sarah Keidel,Katy L. Simonsen,A.M. Sobiesk,Bin Li,F. Stephen Hodi,Georgina V. Long +21 more
TL;DR: The inhibition of two immune checkpoints, LAG-3 andPD-1, provided a greater benefit with regard to progression-free survival than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma.
745
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
Evan J. Lipson,Hussein Abdul-Hassan Tawbi,Dirk Schadendorf,Paolo A. Ascierto,Luis Matamala,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,Juliana Janoski de Menezes,Stéphane Dalle,Ana Arance,Jean-Jacques Grob,Shivani Srivastava,Mena Abaskharoun,Katy L. Simonsen,Bin Li,Georgina V. Long,F. Stephen Hodi +18 more
TL;DR: A novel approach is needed to optimize the benefit-risk profile of immune checkpoint inhibitor therapy in patients with advanced melanoma by developing novel combinations of these medicines.
150
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Georgina V. Long,F. Stephen Hodi,Evan J. Lipson,Dirk Schadendorf,Paolo A. Ascierto,Luis Matamala,Pamela Salman,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,Juliana Janoski de Menezes,Stéphane Dalle,Ana Arance,Jean-Jacques Grob,Sarah Keidel,Anadil Shaikh,A.M. Sobiesk,Sonia C. Dolfi,Hussein Abdul-Hassan Tawbi +19 more
TL;DR: A phase 2/3 trial as discussed by the authors evaluated nivolumab + relatlimab as a fixed-dose combination and found a significant progression-free survival (PFS) benefit over Nivolumaab monotherapy in previously untreated metastatic melanoma patients.
58
Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)
Georgina V. Long,F. Stephen Hodi,Evan J. Lipson,Dirk Schadendorf,Paolo A. Ascierto,Luis Matamala,Pamela Salman,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,Juliana Janoski de Menezes,Stéphane Dalle,Ana Arance,Jean-Jacques Grob,Sarah Keidel,Anadil Shaikh,A.M. Sobiesk,Sonia C. Dolfi,Hussein Abdul-Hassan Tawbi +19 more
TL;DR:
45
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
Hussein Abdul-Hassan Tawbi,F. Stephen Hodi,Evan J. Lipson,Dirk Schadendorf,Paolo A. Ascierto,Luis Matamala,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,Juliana Janoski de Menezes,Stéphane Dalle,Ana Arance,Jean-Jacques Grob,Barbara Ratto,Yuanfang Xu,Sonia C. Dolfi,Georgina V. Long +17 more
TL;DR: In this paper , NIVO + RELA demonstrated a statistically significant progression-free survival (PFS) benefit vs NivO; there was an observed improvement in overall survival (OS) although it was not statistically significant, while the combination also had a descriptively higher confirmed objective response rate (ORR) assessed by blinded independent central review (BICR).
12